BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
The Difficulties of Getting a Green Card in the US- Why ordering takeout or calling the dog walker might lead to a happier relationship
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- Language Learning Stages: Which One Gets Your Vote?
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- ADHD drugs work, but not the way experts thought
- What's your #1 tone
- Really focusing on Succulents: Tips and Procedures
- Investigate Business Mastercard Choices for Better Rewards and Rewards
